enGene Therapeutics Inc.
ENGN- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001980845
In the last 90 days, enGene Therapeutics Inc. insiders filed 1 open-market purchase and 0 sales; 60 institutions reported holding it in 13F filings for Q2 2026, worth $86.5M in total; no superinvestor holds it.
Other share classesENGNW
13F holders, Q4 2023
Institutional positions in enGene Therapeutics Inc. as of Dec 31, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 11
- +11 vs. Q3 2023
- Shares held
- 14.2M
- +14.2M vs. Q3 2023
- Total value
- $130.9M
- +$130.9M vs. Q3 2023
- New holders
- 11
- 0 more added
- Sold out
- 0
- 0 more reduced
Compare with Q3 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting ENGN on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 60 | $86.5M |
| Q1 2026 | 62 | $383.0M |
| Q4 2025 | 58 | $530.8M |
| Q3 2025 | 37 | $279.1M |
| Q2 2025 | 36 | $147.1M |
| Q1 2025 | 31 | $183.4M |
| Q4 2024 | 34 | $274.7M |
| Q3 2024 | 30 | $227.7M |
| Q2 2024 | 30 | $307.1M |
| Q1 2024 | 31 | $536.1M |
| Q4 2023 | 11 | $130.9M |
| Q3 2023 | 0 | $0 |
| Q2 2023 | 0 | $0 |
| Q1 2023 | 0 | $0 |
| Q4 2022 | 0 | $0 |
| Q3 2022 | 0 | $0 |
| Q2 2022 | 0 | $0 |
| Q1 2022 | 0 | $0 |
| Q4 2021 | 0 | $0 |
| Q3 2021 | 0 | $0 |
| Q2 2021 | 0 | $0 |
| Q1 2021 | 0 | $0 |
Institutions, Q4 2023
Shares, value and share of portfolio for each institution holding enGene Therapeutics Inc.; share changes are against Q3 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| FCPM III Services B.V. | 8,677,951 | $80.1M | 23.60% | +8,677,951 | New |
| BVF Inc | 2,251,037 | $20.8M | 0.52% | +2,251,037 | New |
| Blue Owl Capital Holdings LP | 1,234,760 | $11.4M | 2.72% | +1,234,760 | New |
| Omega Fund Management, LLC | 1,131,175 | $10.4M | 8.46% | +1,131,175 | New |
| Vivo Capital, LLC | 678,705 | $6.26M | 0.51% | +678,705 | New |
| Polar Asset Management Partners Inc. | 116,942 | $1.07M | 0.03% | +116,942 | New |
| Royal Bank of Canada | 37,845 | $349.0K | 0.00% | +37,845 | New |
| Goldman Sachs Group Inc | 37,447 | $345.6K | 0.00% | +37,447 | New |
| Citadel Advisors LLC | 20,057 | $185.1K | 0.00% | +20,057 | New |
| UBS Group AG | 1,937 | $17.9K | 0.00% | +1,937 | New |
| Morgan Stanley | 8 | $74 | 0.00% | +8 | New |